Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

laboratorios vijosa s.a. de c.v. - gluconato de calcio - gluconato de calcio....94.00 mg / sacarato de calcio....4.50 mg

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

laboratorios pisa, s.a. de c.v. - gluconato de calcio - gluconato de calcio....1.000 g

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - ferrous gluconate - oral tablet - 300mg

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - quinidine gluconate (unii: r6875n380f) (quinidine - unii:itx08688jl) - quinidine gluconate 324 mg - conversion of atrial fibrillation/flutter in patients with symptomatic atrial fibrillation/flutter whose symptoms are not adequately controlled by measures that reduce the rate of ventricular response, quinidine gluconate is indicated as a means of restoring normal sinus rhythm. if this use of quinidine gluconate does not restore sinus rhythm within a reasonable time (see dosage and administration ), then quinidine gluconate should be discontinued. reduction of frequency of relapse into atrial fibrillation/flutter chronic therapy with quinidine gluconate is indicated for some patients at high risk of symptomatic atrial fibrillation/flutter, generally patients who have had previous episodes of atrial fibrillation/flutter that were so frequent and poorly tolerated as to outweigh, in the judgment of the physician and the patient, the risks of prophylactic therapy with quinidine gluconate. the increased risk of death should specifically be considered. quinidine gluconate should be used only after alternative meas

United States - English - NLM (National Library of Medicine)

richmond pharmaceuticals, inc. - quinidine gluconate (unii: r6875n380f) (quinidine - unii:itx08688jl) - quinidine gluconate 324 mg - conversion of atrial fibrillation/flutter in patients with symptomatic atrial fibrillation/flutter whose symptoms are not adequately controlled by measures that reduce the rate of ventricular response, quinidine gluconate is indicated as a means of restoring normal sinus rhythm. if this use of quinidine gluconate does not restore sinus rhythm within a reasonable time (see dosage and administration ), then quinidine gluconate should be discontinued. reduction of frequency of relapse into atrial fibrillation/flutter chronic therapy with quinidine gluconate is indicated for some patients at high risk of symptomatic atrial fibrillation/flutter, generally patients who have had previous episodes of atrial fibrillation/flutter that were so frequent and poorly tolerated as to outweigh, in the judgment of the physician and the patient, the risks of prophylactic therapy with quinidine gluconate. the increased risk of death should specifically be considered. quinidine gluconate should be used only after alternative meas

United States - English - NLM (National Library of Medicine)

watson laboratories, inc. - quinidine gluconate (unii: r6875n380f) (quinidine - unii:itx08688jl) - tablet, extended release - 324 mg - in patients with symptomatic atrial fibrillation/flutter whose symptoms are not adequately controlled by measures that reduce the rate of ventricular response, quinidine gluconate is indicated as a means of restoring normal sinus rhythm. if this use of quinidine gluconate does not restore sinus rhythm within a reasonable time (seedosage and administration ), then quinidine gluconate should be discontinued. chronic therapy with quinidine gluconate is indicated for some patients at high risk of symptomatic atrial fibrillation/flutter, generally patients who have had previous episodes of atrial fibrillation/flutter that were so frequent and poorly tolerated as to outweigh, in the judgment of the physician and the patient, the risks of prophylactic therapy with quinidine gluconate. the increased risk of death should specifically be considered. quinidine gluconate should be used only after alternative measures (e.g., use of other drugs to control the ventricular rate) have been found to be inadequate. in patients

United States - English - NLM (National Library of Medicine)

carilion materials management - quinidine gluconate (unii: r6875n380f) (quinidine - unii:itx08688jl) - quinidine gluconate 324 mg - conversion of atrial fibrillation/flutter in patients with symptomatic atrial fibrillation/flutter whose symptoms are not adequately controlled by measures that reduce the rate of ventricular response, quinidine gluconate is indicated as a means of restoring normal sinus rhythm. if this use of quinidine gluconate does not restore sinus rhythm within a reasonable time (see dosage and administration ), then quinidine gluconate should be discontinued. reduction of frequency of relapse into atrial fibrillation/flutter chronic therapy with quinidine gluconate is indicated for some patients at high risk of symptomatic atrial fibrillation/flutter, generally patients who have had previous episodes of atrial fibrillation/flutter that were so frequent and poorly tolerated as to outweigh, in the judgment of the physician and the patient, the risks of prophylactic therapy with quinidine gluconate. the increased risk of death should specifically be considered. quinidine gluconate should be used only after alternative meas

United States - English - NLM (National Library of Medicine)

dentsply llc. professional division trading as "dentsply professional" - chlorhexidine gluconate (unii: mor84mud8e) (chlorhexidine - unii:r4ko0dy52l) - chlorhexidine gluconate 1.2 mg in 1 ml - chlorhexidine gluconate oral rinse should not be used by persons who are known to be hypersensitive to chlorhexidine gluconate or other formula ingredients.

United States - English - NLM (National Library of Medicine)

akorn - chlorhexidine gluconate (unii: mor84mud8e) (chlorhexidine - unii:r4ko0dy52l) - chlorhexidine gluconate 1.2 mg in 1 ml - chlorhexidine gluconate oral rinse, 0.12% should not be used by persons who are known to be hypersensitive to chlorhexidine gluconate or other formula ingredients.

United States - English - NLM (National Library of Medicine)

llc federal solutions - chlorhexidine gluconate (unii: mor84mud8e) (chlorhexidine - unii:r4ko0dy52l) - chlorhexidine gluconate 1.2 mg in 1 ml - indication chlorhexidine gluconate oral rinse is indicated for use between dental visits as part of a professional program for the treatment of gingivitis as characterized by redness and swelling of the gingivae, including gingival bleeding upon probing. chlorhexidine gluconate oral rinse has not been tested among patients with acute necrotizing ulcerative gingivitis (anug). for patients having coexisting gingivitis and periodontitis, see precautions. contraindications chlorhexidine gluconate oral rinse should not be used by persons who are known to be hypersensitive to chlorhexidine gluconate or other formula ingredients. pediatric use clinical effectiveness and safety of chlorhexidine gluconate oral rinse have not been established in children under the age of 18.